Knockdown of ANRIL by siRNA restored the ability of two tumor cell lines (A375 and OM431) to transcribe INK4A and INK4B. This reduced the cell’s ability to migrate and form colonies and ANRIL might therefore be a valid therapeutic target [96]. Here, CDKN2B-AS1 is linked to neoplasm.